氯胺酮在危重症成人治疗中的重新兴起
本文通过检索PubMed截至2018年8月发表的主要文献,纳入病例报告、观察性研究(队列、病例对照)和随机对照试验,评估氯胺酮在成人危重症患者(ICU与急诊科、非围手术期、静脉或肌内给药)中的证据。讨论范围包括疼痛、镇静、哮喘持续状态、酒精戒断综合征、癫痫持续状态和急性行为心理障碍。结论认为氯胺酮在上述多种疾病状态中提示潜在获益,但仍需进一步证据来验证其在危重症中的使用。
要点
- 综述纳入病例报告、观察性研究与随机对照试验,聚焦ICU和急诊科成人危重症患者的静脉或肌内氯胺酮使用。
- 讨论用途包括疼痛、镇静、哮喘持续状态、酒精戒断综合征、癫痫持续状态和急性行为心理障碍。
- 结论认为氯胺酮在疼痛、酒精戒断综合征、癫痫持续状态和急性躁动中提示潜在获益。
- 作者指出仍需进一步证据验证氯胺酮在危重症中的使用。
适用人群与场景
- 纳入病例报告、观察性研究(队列、病例对照)和随机对照试验,对象为18岁及以上、非围手术期、使用静脉或肌内氯胺酮的患者。
- 讨论聚焦ICU和急诊科场景中的危重症患者。
研究设计与关键结果
- 文献综述:检索PubMed截至2018年8月发表的主要文献,纳入病例报告、观察性研究(队列、病例对照)和随机对照试验,评估氯胺酮的剂量、结局与不良反应。
- 证据按用途组织:疼痛、镇静、哮喘持续状态、酒精戒断综合征、癫痫持续状态和急性行为心理障碍;证据评价结合相关指南推荐。
证据类型、等级与局限
- 证据类型:文献综述,纳入病例报告、观察性研究(队列、病例对照)和随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为氯胺酮在疼痛、酒精戒断综合征、癫痫持续状态和急性躁动等危重症疾病状态中提示潜在获益。
- 作者指出仍需进一步证据验证氯胺酮在危重症中的使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the evidence and discuss the risks and clinical relevance of ketamine for the treatment of various disease states impacting the adult critically ill population.
DATA SOURCES: A literature review was performed using PubMed evaluating primary literature published until August 2018.
STUDY SELECTION: Case reports, observational studies (cohort, case-control), and randomized controlled trials involving patients 18 years and older in a nonperioperative setting using either IV or intramuscular ketamine were included for analysis. Uses of ketamine discussed focused on critically ill patients in the ICU and emergency department settings.
DATA EXTRACTION: Included studies were evaluated for dosing, outcomes, and adverse effects of ketamine. For each study, the design, population, intervention, investigated outcomes, and results were assessed.
DATA SYNTHESIS: The evidence was organized according to use of ketamine, which included pain, sedation, status asthmaticus, alcohol withdrawal syndrome, status epilepticus, and acute behavioral psychologic disturbances. Evaluation of the evidence was based on the included primary literature along with any related guideline recommendations.
CONCLUSIONS: Ketamine has suggested potential benefit in several disease states impacting critically ill patients including pain, alcohol withdrawal syndrome, status epilepticus, and acute agitation. Further supporting evidence is needed to validate its use in the setting of critical illness.
参考来源
- Hurth KP, Jaworski A, Thomas KB, et al. The Reemergence of Ketamine for Treatment in Critically Ill Adults. Crit Care Med. 2020. PMID: 32317593. doi:10.1097/CCM.0000000000004335
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。